SCHEMBL16536680

SCHEMBL16536680

CN(C)C(=O)c1cc2cc(Br)cnc2[nH]1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 2/20 0.44
FGFR2 P21802 1/20 0.44
MAP4K1 Q92918 2/20 0.41
ABL1 P00519 6/20 0.39
SRC P12931 3/20 0.39
CCNK O75909 1/20 0.39
CDK12 Q9NYV4 1/20 0.39
NUDT1 P36639 1/20 0.38
AURKA O14965 1/20 0.38
DAPK3 O43293 1/20 0.38
JAK2 O60674 1/20 0.38
PRKD3 O94806 1/20 0.38
MAP4K4 O95819 1/20 0.38
PAK4 O96013 1/20 0.38
NTRK1 P04629 1/20 0.38
FYN P06241 1/20 0.38
RET P07949 1/20 0.38
MET P08581 1/20 0.38
PDGFRB P09619 1/20 0.38
PIM1 P11309 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15738800 0.81 DAO (0.45) FGFR1ABL1SRCAURKADAPK3
SCHEMBL29092443 0.80 ABL1 (0.57) ABL1SRC
SCHEMBL16537139 0.80 CREBBP (0.46) FGFR1FGFR2ABL1SRCCCNK
SCHEMBL22479196 0.80 ABL1 (0.41) FGFR1ABL1SRCAURKADAPK3
SCHEMBL23926508 0.77 KMT2A (0.42) FGFR1FGFR2MAP4K1CCNKCDK12
SCHEMBL14653999 0.77 KDM4E (0.46) FGFR1ABL1SRCAURKADAPK3
SCHEMBL2023929 0.77 FGFR1 (0.43) FGFR1FGFR2MAP4K1CCNKCDK12
SCHEMBL29617789 0.77 FGFR1 (0.43) FGFR1FGFR2MAP4K1CCNKCDK12
Hydrochloric Acid SCHEMBL30991387 0.76 FGFR1 (0.42) FGFR1FGFR2MAP4K1CCNKCDK12
SCHEMBL1313379 0.75 KDM4E (0.48) ABL1SRCHTTSMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9725465-B2 Biaryl acetamide compounds and methods of use thereof AMBIT BIOSCIENCES CORPORATION (US) 2017-08-08 US disclosed
EP-3039021-A1 BIARYL ACETAMIDE COMPOUNDS AND METHODS OF USE THEREOF Ambit Biosciences Corporation (US) 2016-07-06 EP disclosed
WO-2015031613-A1 BIARYL ACETAMIDE COMPOUNDS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORPORATION (US) 2015-03-05 WO disclosed
US-20150065468-A1 BIARYL ACETAMIDE COMPOUNDS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORP (US) 2015-03-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150065468-A1 BIARYL ACETAMIDE COMPOUNDS AND METHODS OF USE THEREOF ERBB2, ERBB3, AADAC FGFR1 102/4885FGFR2 100/4885MAP4K1 337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.